TScan Therapeutics (TCRX) Other Non-Current Liabilities (2020 - 2025)
TScan Therapeutics' (TCRX) quarterly Other Non-Current Liabilities came in at $278000.0 in Q3 2025, up 90.41% year-on-year from $146000.0 in Q3 2024, and up 146.02% on a QoQ basis from $113000.0 in Q2 2025.
TScan Therapeutics (TCRX) Other Non-Current Liabilities (2020 - 2025) Analysis & Trends
TScan Therapeutics (TCRX) has 6 years of Other Non-Current Liabilities data on file, last reported at $278000.0 in Q3 2025.
- On a quarterly basis, Other Non-Current Liabilities rose 90.41% year-over-year to $278000.0 in Q3 2025; TTM through Sep 2025 was $278000.0, a 90.41% increase from a year earlier, with the FY2024 full-year figure at $135000.0, changed N/A from the prior year.
- Other Non-Current Liabilities for Q3 2025 stood at $278000.0, up from $113000.0 in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for TCRX reached as high as $278000.0 in Q3 2025 and fell as low as $12000.0 in Q3 2023.
- Historically, Other Non-Current Liabilities has averaged $118600.0 across 5 years, with a median of $97000.0 in 2021.
- Across the five-year window, Other Non-Current Liabilities sank 87.63% in 2023 and jumped 1116.67% in 2024, its largest moves.
- Year by year, Other Non-Current Liabilities stood at $97000.0 in 2021, then plunged by 49.48% to $49000.0 in 2022, then slumped by 75.51% to $12000.0 in 2023, then surged by 1025.0% to $135000.0 in 2024, then soared by 105.93% to $278000.0 in 2025.
- Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $278000.0 in Q3 2025, $113000.0 in Q2 2025, and $124000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | TScan Therapeutics | 100.59 Mn | -27.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 278,000.00 |
| Jun 30, 2025 | 113,000.00 |
| Mar 31, 2025 | 124,000.00 |
| Dec 31, 2024 | 135,000.00 |
| Sep 30, 2024 | 146,000.00 |
| Sep 30, 2023 | 12,000.00 |
| Jun 30, 2023 | 24,000.00 |
| Mar 31, 2023 | 36,000.00 |
| Dec 31, 2022 | 49,000.00 |
| Sep 30, 2022 | 97,000.00 |
| Jun 30, 2022 | 97,000.00 |
| Mar 31, 2022 | 97,000.00 |
| Dec 31, 2021 | 97,000.00 |
| Sep 30, 2021 | 236,000.00 |
| Jun 30, 2021 | 238,000.00 |
| Dec 31, 2020 | 238,000.00 |